Biosense Webster, Inc. Reports Compelling Results From Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH Catheter
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the 12-month safety and effectiveness results of the THERMOCOOL® SMARTTOUCH™ Catheter and Software Module in the treatment of symptomatic, drug refractory, paroxysmal atrial fibrillation from the ground-breaking SMART-AF Investigational Device Exemption (IDE) clinical trial. The results of the trial were presented at the Heart Rhythm Society’s 34th Annual Scientific Sessions in Denver, CO, by Dr. Andrea Natale, a member of the study Advisory Committee and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX.
Help employers find you! Check out all the jobs and post your resume.
DIAMOND BAR, Calif.--(BUSINESS WIRE)--Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the 12-month safety and effectiveness results of the THERMOCOOL® SMARTTOUCH™ Catheter and Software Module in the treatment of symptomatic, drug refractory, paroxysmal atrial fibrillation from the ground-breaking SMART-AF Investigational Device Exemption (IDE) clinical trial. The results of the trial were presented at the Heart Rhythm Society’s 34th Annual Scientific Sessions in Denver, CO, by Dr. Andrea Natale, a member of the study Advisory Committee and Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, TX.
Help employers find you! Check out all the jobs and post your resume.